Cargando…
The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes
The authors discuss the strategy of use of incretin hormones in type 2 diabetes treatment in the context of cardiovascular complications. The results of the phase III study on human GLP-1 (Glucagon-like peptide-1) analogue-liraglutide have been presented under common acronym LEAD (Liraglutide-Effect...
Autores principales: | Kinalska, Ida, Bednarska-Chabowska, Dorota, Adamiec-Mroczek, Joanna, Hak, Łukasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302114/ https://www.ncbi.nlm.nih.gov/pubmed/22462016 http://dx.doi.org/10.5402/2012/625809 |
Ejemplares similares
-
Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
por: Schnabel, Catherine A, et al.
Publicado: (2006) -
Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes
por: Gleeson, Jeremy M., et al.
Publicado: (2005) -
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010) -
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
por: Solini, Anna, et al.
Publicado: (2023) -
Understanding the Cardiovascular Effects of Incretin
por: Yoon, Ji Sung, et al.
Publicado: (2011)